Whether gaining further insights on the molecular pathways that could link MYCN and TAL1 expression is needed, these results indicates that MYCN is a potential component of pediatric T-ALL genesis and a candidate for targeted therapy. The gene discussed is MYCN; the disease is acute lymphoblastic leukemia.